View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
Do you know what they contain? Match the brand names in Section I with the generic ingredients in Section II.
_____ 1. Humira (Abbott)
_____ 2. Enbrel (Amgen/Pfizer)
_____ 3. Kineret (Amgen)
_____ 4. Remicade (Centocor Ortho Biotech)
This tumor necrosis factor (TNF) blocker is indicated for patients with moderately to severely active rheumatoid arthritis (RA). Common adverse reactions include infections and injection-site reactions. The drug should be discontinued if a serious infection or sepsis develops.
Given with methotrexate, this TNF blocker slows the progression of joint damage in patients with moderately to severely active RA. Patients may experience acute infusion reaction with fever, chills, pruritus, and rash within 1 to 2 hours of administration. If a serious infection develops, therapy should be stopped.
This drug can be used alone or with methotrexate or other disease-modifying antirheumatic drugs (DMARDs). The most common adverse reactions include injection-site reactions, infections, headache, and rash. Monitor patients for severe allergic reactions, including anaphylaxis.
A recombinant interleukin-1 (IL-1) receptor antagonist, this drug binds to IL-1 type I receptors on target cells to slow the progression of structural damage. The drug can be combined with DMARDs other than TNF-blocking agents. The most common adverse reaction is local injection-site reactions.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top